ライフサイエンスコーパス: pneumococcal

1 P) is considered a bacterial disease, mainly pneumococcal.

2 Pneumococcal ability to grow in the IAV-infected LRT dep

3 When compared with carriers among controls, pneumococcal absolute abundances were significantly high

4 Bacterial and pneumococcal abundances were determined in raw saliva wi

5 Finally, pneumococcal abundances were highest in carriage events

6 Pneumococcal acquisition and colonization density is pro

7 Pneumococcal adaptation to IAV-induced inflammation and

8 dy in the human host, a major factor driving pneumococcal adaptation.

9 Pneumococcal adherence to adult human nasal fluid was se

10 avi, the World Bank, and donors launched the pneumococcal Advance Market Commitment, which helped cou

11 ecific NPNM was calculated with the ratio of pneumococcal and Hib meningitis case fatality to pneumoc

12 mococcal and Hib meningitis case fatality to pneumococcal and Hib meningitis NPNM case fatality.

13 Under current coverage levels, pneumococcal and rotavirus vaccines prevent 23.8 million

14 IgGs was examined using well-defined rabbit pneumococcal antisera.

15 to 2 Dutch hospitals between 2000-2011 with pneumococcal bacteremia.

16 t the complete respiratory ecosystem affects pneumococcal behaviour following challenge, with low-den

17 over five years and 83 (-10, 242) additional pneumococcal-CAP cases, with together 8 (-2, 24) additio

18 analysed samples from the Experimental Human Pneumococcal Carriage (EHPC) project.

19 We assessed changes in pneumococcal carriage and antibiotic susceptibility patt

20 ader serotype coverage and potency to reduce pneumococcal carriage are needed.

21 Changes in pneumococcal carriage by age (<1 year, 1-4 years, adults

22 2015 ("late PCV13"), and had nasopharyngeal pneumococcal carriage compared with 7-valent pneumococca

23 In this post-hoc analysis of midnasal pneumococcal carriage in a community-based, randomized p

24 e effects of influenza-like illness (ILI) on pneumococcal carriage in community-dwelling older adults

25 In conclusion, use of qPCR suggests that pneumococcal carriage in Portuguese elderly is approxima

26 From 2009-2016, we monitored pneumococcal carriage in southern Israel, where children

27 ree geographically distinct WGS data sets of pneumococcal carriage isolates.

28 at baseline are associated with consecutive pneumococcal carriage outcome (non-carrier, low-dense an

29 We estimated pneumococcal carriage prevalence and serotypes among Por

30 to mothers given influenza vaccine had lower pneumococcal carriage rates compared to influenza-positi

31 09-2013, we performed annual cross-sectional pneumococcal carriage surveys in 2 sites: Kibera (childr

32 Pneumococcal carriage was associated with exposure to yo

33 tcome (non-carrier, low-dense and high-dense pneumococcal carriage), independent of LAIV co-administr

34 otential benefits to including non-conserved pneumococcal carrier proteins.

35 1% (95% CI 72-88) vaccinated with PCV13 were pneumococcal carriers (P = .023), whereas no differences

36 class A PBPs have an autonomous role during pneumococcal cell wall synthesis.

37 nhibited growth and reduced the extension of pneumococcal chains.

38 enuated influenza vaccine (LAIV), successive pneumococcal challenge, and the healthy adult nasal micr

39 rapid bacterial proliferation 4 to 6 h after pneumococcal challenge.

40 cells.Methods: We collected BAL from healthy pneumococcal-challenged participants aged 18-49 years.

41 ox imbalance increased the expression of the pneumococcal chaperone/protease HtrA.

42 leading to loss of immunological control of pneumococcal colonisation, increased inflammation, tissu

43 be an important consideration in studies of pneumococcal colonisation.

44 ion schedule, there have been declines in VT pneumococcal colonization and disease in children aged <

45 of the serotype distribution associated with pneumococcal colonization and disease is essential for e

46 stigated the effects of this introduction on pneumococcal colonization and invasive disease in childr

47 his gap, we adapted an infant mouse model of pneumococcal colonization and transmission to investigat

48 ater odds, respectively, of vaccine-serotype pneumococcal colonization at ages 13-24 months.

49 e that L. murinus provides a barrier against pneumococcal colonization in a respiratory dysbiosis mod

50 ILI exacerbates pneumococcal colonization of the airways in older adults

51 or approximately 3 months after experimental pneumococcal colonization.

52 I 17.7-33.0) decrease in multidrug-resistant pneumococcal colonization.

53 e on invasive pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (CAP).

54 ) and coded hospitalizations for noninvasive pneumococcal community-acquired pneumonia (PnCAP) to eva

55 impact on invasive pneumococcal disease and pneumococcal community-acquired pneumonia differed by ag

56 sigma(X) mediates the timely shut-off of the pneumococcal competence cycle, preserving cell fitness.

57 The pneumococcal competence system facilitates genetic trans

58 3 months after transplant, giving 3 doses of pneumococcal conjugate vaccine (PCV) followed by either

59 Pneumococcal conjugate vaccine (PCV) implementation has

60 e outbreaks have not been reported following pneumococcal conjugate vaccine (PCV) implementation.

61 t in comparable settings.Fifteen years after pneumococcal conjugate vaccine (PCV) introduction and 5

62 ccine-type pneumococcal meningitis following pneumococcal conjugate vaccine (PCV) introduction.

63 markedly declined following 7- and 13-valent pneumococcal conjugate vaccine (PCV) introductions world

64 Universal pneumococcal conjugate vaccine (PCV) programs began in I

65 Reduced-dose pneumococcal conjugate vaccine (PCV) schedules are under

66 ey will need to consider whether to continue pneumococcal conjugate vaccine (PCV) use at full cost or

67 den data to support decisions on introducing pneumococcal conjugate vaccine (PCV).

68 Kenya introduced 10-valent pneumococcal conjugate vaccine (PCV10) among children <1

69 Zambia introduced a 10-valent pneumococcal conjugate vaccine (PCV10) in July 2013 usin

70 ess the effect of introduction of ten-valent pneumococcal conjugate vaccine (PCV10) on pneumonia mort

71 outine infant immunisation with a ten-valent pneumococcal conjugate vaccine (PCV10) using three prima

72 Nepalese infants receive ten-valent pneumococcal conjugate vaccine (PCV10) with a 1 month in

73 ompared with those included in the 13-valent pneumococcal conjugate vaccine (PCV13) and the remaining

74 icipants received DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, fol

75 dy describes the immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) during and after

76 Therefore, vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-va

77 removal of one primary dose of the 13-valent pneumococcal conjugate vaccine (PCV13) from the existing

78 Cambodia introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in January 2015 u

79 The impact of 13-valent pneumococcal conjugate vaccine (PCV13) introduction on t

80 In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in

81 estimate in relation to PPV23/non-13-valent pneumococcal conjugate vaccine (PCV13) serotype pneumoni

82 g programmatic introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), there is residua

83 itis has decreased since the introduction of pneumococcal conjugate vaccine (PCV7 and PCV13).

84 pneumococcal carriage compared with 7-valent pneumococcal conjugate vaccine (PCV7) immunized children

85 zard ratios (aHRs) for OM comparing 7-valent pneumococcal conjugate vaccine (PCV7)-era (2006-2010) an

86 pneumococcal, many can be prevented by PCVs.Pneumococcal conjugate vaccine (PCV7/PCV13) implementati

87 o 6 years old (vaccinated with the 13-valent pneumococcal conjugate vaccine [PCV13] as part of the Ex

88 Rapid scale-up and widespread use of the pneumococcal conjugate vaccine and sustained use of the

89 ed by a booster at 11 months and a 10-valent pneumococcal conjugate vaccine at 2, 4, and 11 months af

90 ge from a "3 + 0" infant schedule (13-valent pneumococcal conjugate vaccine at 2, 4, and 6 months) to

91 The study was conducted before pneumococcal conjugate vaccine implementation in Israel.

92 en a decline in pneumococcal meningitis post-pneumococcal conjugate vaccine introduction in Senegal.

93 ntile) to 91% (75th percentile) for 7-valent pneumococcal conjugate vaccine serotypes and from 58% to

94 om 58% to 63% for the 6 additional 13-valent pneumococcal conjugate vaccine serotypes.

95 older adults, since introducing a 13-valent pneumococcal conjugate vaccine to the paediatric immunis

96 serotypes that are included in the 10-valent pneumococcal conjugate vaccine.

97 tic limitations, the protection conferred by pneumococcal conjugate vaccines (PCVs) against pediatric

98 Introduction of pneumococcal conjugate vaccines (PCVs) has shown a marke

99 Pneumococcal conjugate vaccines (PCVs) have reduced pneu

100 Pneumococcal conjugate vaccines (PCVs) have significantl

101 The continuing impact of pneumococcal conjugate vaccines (PCVs) in regions with h

102 There are concerns that pneumococcal conjugate vaccines (PCVs) in sub-Saharan Af

103 The introduction of pneumococcal conjugate vaccines (PCVs) into childhood va

104 moniae, an important human pathogen, and the pneumococcal conjugate vaccines (PCVs), which target onl

105 cale studies of households, we estimate that pneumococcal conjugate vaccines and live attenuated rota

106 Pneumococcal conjugate vaccines have been successful, bu

107 CAP and for assessing the efficacy of future pneumococcal conjugate vaccines that are under developme

108 0), representing a 58% (UR 22-78) decline in pneumococcal deaths and an 81% (59-91) decline in Hib de

109 00 [5600-10 700]) had the highest numbers of pneumococcal deaths in 2015.

110 Between 2000 and 2015, estimates of pneumococcal deaths in Indian children aged 1-59 months

111 capacity was correlated with nasopharyngeal pneumococcal density (r = 0.61, P = 0.025).Conclusions:

112 iduals were positively correlated with nasal pneumococcal density (r = 0.71; P = 0.029).

113 Nasopharyngeal pneumococcal density was higher in pediatric pneumonia p

114 lyzed data on vaccination and nasopharyngeal pneumococcal detection among children <5 years old with

115 s old, we evaluated PCV13 impact on invasive pneumococcal disease (IPD) among adults with and without

116 evaluated PCV13 indirect effects on invasive pneumococcal disease (IPD) among adults with and without

117 We used laboratory data for invasive pneumococcal disease (IPD) and coded hospitalizations fo

118 rus (PLWH) are at increased risk of invasive pneumococcal disease (IPD) and community-acquired pneumo

119 of a 1+1 (3, 12 month) schedule on invasive pneumococcal disease (IPD) and pneumococcal community-ac

120 ludes national laboratory data from invasive pneumococcal disease (IPD) cases affecting pediatric and

121 Invasive pneumococcal disease (IPD) cases were identified through

122 is experiencing a rapid increase in invasive pneumococcal disease (IPD) caused by serotypes 8, 12F, a

123 Invasive pneumococcal disease (IPD) caused by Streptococcus pneum

124 Invasive pneumococcal disease (IPD) data for January 2012-Decembe

125 tion has led to a sharp decrease in invasive pneumococcal disease (IPD) due to the reduction in PCV s

126 ifferent clinical manifestations of invasive pneumococcal disease (IPD) have thus far mainly been exp

127 sess the change in the incidence of invasive pneumococcal disease (IPD) in adults after the introduct

128 tiveness studies against serotype 3 invasive pneumococcal disease (IPD) in children have shown incons

129 am has affected the epidemiology of invasive pneumococcal disease (IPD) in individuals treated with i

130 ograms in reducing the incidence of invasive pneumococcal disease (IPD) in Taiwanese children.

131 Although the invasive pneumococcal disease (IPD) incidence due to vaccine sero

132 PCV vaccination program on cases of invasive pneumococcal disease (IPD), all-cause pneumonia (ACP), a

133 g meningitis, a more severe form of invasive pneumococcal disease (IPD), are largely unknown.

134 rugs may lessen organ damage during invasive pneumococcal disease (IPD).

135 pharyngeal commensal that can cause invasive pneumococcal disease (IPD).

136 CV13, direct and indirect impact on invasive pneumococcal disease and pneumococcal community-acquired

137 To assess the substantial remaining pneumococcal disease burden after introduction of severa

138 Lung inhaled DEPs increase susceptibility to pneumococcal disease by leading to loss of immunological

139 Increasing numbers of cases of invasive pneumococcal disease in fully vaccinated children have o

140 otype 1 is the predominant cause of invasive pneumococcal disease in sub-Saharan Africa, but the mech

141 ineage causing non-vaccine serotype invasive pneumococcal disease in the PCV13 period.

142 ic setting; however, to significantly reduce pneumococcal disease in these settings, PCVs with broade

143 e incidence of non-vaccine serotype invasive pneumococcal disease in young children and older people

144 In older adults pneumococcal disease is strongly associated with respira

145 emonstrate the potential for PCV20 to expand pneumococcal disease protection.

146 tanding of the link between DEP exposure and pneumococcal disease risk, and we confirmed our findings

147 ults and found incidence rates comparable to pneumococcal disease where vaccines are recommended.

148 vaccines (PCVs) have significantly decreased pneumococcal disease worldwide; however, expanding serot

149 reporting the incidence of IPD, non-invasive pneumococcal disease, hospitalizations, and mortality in

150 has had rising non-vaccine serotype invasive pneumococcal disease, most notably in older adults, sinc

151 iage of Streptococcus pneumoniae to invasive pneumococcal disease.

152 as one of the most common causes of invasive pneumococcal disease.

153 on of urine samples from individuals without pneumococcal disease.

154 are at increased risk of developing invasive pneumococcal disease.

155 protection against vaccine-serotype invasive pneumococcal disease.

156 as reduced carriage of vaccine serotypes and pneumococcal disease.

157 occal conjugate vaccines (PCVs) have reduced pneumococcal diseases globally.

158 ctions (NA-LRI) are generally not considered pneumococcal diseases.

159 tions (NA-LRIs) are generally not considered pneumococcal diseases.

160 doglycan-synthesizing machineries within the pneumococcal divisome (FtsW/PBP2x) and elongasome (RodA/

161 Pneumococcal DNA detected in the BAL samples of Spn-colo

162 We investigated the presence of pneumococcal DNA in saliva samples collected in the 2014

163 Pneumococcal DNA was detected with quantitative-PCRs tar

164 be applied to other settings with different pneumococcal epidemiology or with immature programmes an

165 CV13 in children has shown a clear impact in pneumococcal epidemiology reducing the burden of IPD in

166 nt to explain invasiveness, suggesting other pneumococcal factors are involved in progression to inva

167 Findings suggest that changes in pneumococcal gene expression occurring in the lung envir

168 ISPRi-seq to assess bottlenecks and identify pneumococcal genes important in a murine pneumonia model

169 e and other bacteria drives high within-host pneumococcal genetic diversity.

170 Pneumococcal genetic variation explains a large amount o

171 Pneumococcal genomic surveys elucidate PCV effects on po

172 variants, and indicates that information on pneumococcal genotype is important for the diagnostic an

173 In this study, knowledge of pneumococcal genotypic variants improved the clinical ri

174 Pneumococcal growth with hemoglobin was unusually robust

175 morbidities, administration of influenza and pneumococcal immunizations, and prescription of long-ter

176 IBD patients by measuring serotype-specific pneumococcal immunoglobulin G antibody concentrations at

177 nd reduces bacterial loads during concurrent pneumococcal infection and allergic airway inflammation

178 t OPN significantly affects vulnerability to pneumococcal infection in atopic asthma.

179 PN affects inflammation and vulnerability to pneumococcal infection in atopic asthma.

180 Inflammation triggered by pneumococcal infection is necessary for bacterial cleara

181 inary antigen testing (UAT) when identifying pneumococcal infection would allow for antibiotic de-esc

182 tablished lung fibrosis completely inhibited pneumococcal infection-induced fibrosis exacerbation as

183 fibrosis and further increased in mice with pneumococcal infection-induced lung fibrosis exacerbatio

184 tion is associated with an increased risk of pneumococcal infection.

185 and thereby causes extreme susceptibility to pneumococcal infection.

186 Pneumococcal infections can lead to uncontrolled hyperin

187 ease (IBD) are at increased risk of invasive pneumococcal infections.

188 te the role of ATP in neutrophil response to pneumococcal infections.

189 The concentration of pneumococcal inoculum (1 x 10(6) to 1 x 10(8) CFU/mouse)

190 el findings provide intriguing insights into pneumococcal interactions with its obligate human host.

191 yzed IPD cases from 2011 to 2016 for which a pneumococcal isolate was sent to the National Reference

192 dertook whole-genome sequencing (WGS) of 660 pneumococcal isolates collected through surveys from hea

193 Nasopharyngeal cultures were processed for pneumococcal isolation and serotyping.

194 Major pneumococcal lineages in the PCV period were identified

195 genome-wide association studies to identify pneumococcal lineages, genes, and allelic variants assoc

196 CbpD and CibAB are highly conserved across pneumococcal lineages, indicating evolutionary advantage

197 lar macrophages, and consequently, increased pneumococcal loads within the lungs and translocation in

198 Pneumococcal lysates and the sputum fraction were separa

199 tract infections are usually not considered pneumococcal, many can be prevented by PCVs.

200 although NA-LRIs are usually not considered pneumococcal, many can be prevented by PCVs.Pneumococcal

201 although NA-LRIs are usually not considered pneumococcal, many can in fact be prevented by PCVs.

202 PCV13 vaccination is effective in preventing pneumococcal meningitis among children <5 years of age i

203 lmost half of variation in susceptibility to pneumococcal meningitis and one-third of variation in se

204 e distribution among children with confirmed pneumococcal meningitis at HCH and acute respiratory inf

205 Pneumococcal meningitis case fatality rate was 6-fold hi

206 Nearly half the pneumococcal meningitis cases successfully serotyped (46

207 We also evaluated declines in vaccine-type pneumococcal meningitis following pneumococcal conjugate

208 In children, the incidence of pneumococcal meningitis has decreased since the introduc

209 There has been a decline in pneumococcal meningitis post-pneumococcal conjugate vacc

210 Following PCV10 introduction, pneumococcal meningitis, bacterial meningitis, and pneum

211 We evaluated the impact of PCV13 on pneumococcal meningitis.

212 perinfection, facilitating identification of pneumococcal pathogenesis-related genes.

213 Our results support a model in which mature pneumococcal peptidoglycan is synthesized by three funct

214 , the largest iron reservoir in the body, on pneumococcal physiology.

215 case was defined as PPV23 serotype-specific pneumococcal pneumonia and a control as non-PPV23 seroty

216 lammation and bacterial dissemination during pneumococcal pneumonia by promoting host defenses, sugge

217 ctiveness (VE) of PPV23 against vaccine-type pneumococcal pneumonia in a cohort of adults hospitalise

218 evaluated the role of AnxA1 and FPR2 during pneumococcal pneumonia in mice.

219 iplied by adjusted ARI incidence to estimate pneumococcal pneumonia incidence.

220 hu-pGSN improves outcomes in a highly lethal pneumococcal pneumonia model when given after a clinical

221 neumonia and a control as non-PPV23 serotype pneumococcal pneumonia or nonpneumococcal pneumonia.

222 Rationale: Pneumococcal pneumonia remains a global health problem.

223 We investigated the pathogenesis of pneumococcal pneumonia using clinical specimens collecte

224 e BALB/c mice, which are highly resistant to pneumococcal pneumonia when infected with other serotype

225 s as a novel therapeutic strategy to control pneumococcal pneumonia.

226 were worse at protecting naive mice against pneumococcal pneumonia.

227 L1 in macrophages confers protection against pneumococcal pneumonia.

228 challenge) with rhu-pGSN in a mouse model of pneumococcal pneumonia.

229 100 serotypes were initially included in the pneumococcal polysaccharide conjugate vaccine (PCV) in 2

230 jugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 2 months la

231 (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months lat

232 Vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23) is available

233 (PCV) followed by either a dose of 23-valent pneumococcal polysaccharide vaccine (PSV23) or a fourth

234 of the UAD-2 assay was achieved by capturing pneumococcal polysaccharides with serotype-specific mono

235 of accessory genes to predict changes in the pneumococcal population after vaccination, hypothesizing

236 nize new human hosts is a critical aspect of pneumococcal population biology and a prerequisite for i

237 genomic surveillance of the dynamics of the pneumococcal population with increased geographical repr

238 ance was highly dependent on the circulating pneumococcal population, further highlighting the advant

239 predicting the impact of an intervention on pneumococcal populations with potential application to o

240 nvasiveness of the pre- and post-PCV-carried pneumococcal populations.

241 were used to investigate microaspiration and pneumococcal presence in the lower airways.

242 ination in a lethal challenge mouse model of pneumococcal respiratory infection.

243 ons, a type of control measures that exploit pneumococcal seasonality to help reduce IPDs.

244 s about the components and the mechanisms of pneumococcal seasonality.

245 The incidence of pneumococcal sepsis in children shortly after introducti

246 We used the PubMLST and Global Pneumococcal Sequencing Project databases to quantify th

247 Prevalent in sub-Saharan Africa, pneumococcal serotype 1 is atypical in that it is rarely

248 mixed-species OM; colonizing and OM-causing pneumococcal serotype distributions were more similar to

249 pbp1b641C pneumococci, after controlling for pneumococcal serotype, antibiotic resistance, and patien

250 rying commonly recognized pneumonia invasive pneumococcal serotypes ([PnIST] 1, 5, 7F, 14, and 19A) d

251 term infants, except for pertussis toxin and pneumococcal serotypes 4 and 19F after the primary serie

252 0.6% among all preterm infants overall), and pneumococcal serotypes 4, 6B, 18C, and 23F between 45.8%

253 y phenotypic and genotypic methods to detect pneumococcal serotypes and antimicrobial resistance.

254 d Health Organization criterion for studying pneumococcal serotypes carried without isolating bacteri

255 Pneumococcal serotypes causing single-species OM (NTHi a

256 gainst CAAP attributable to vaccine-targeted pneumococcal serotypes resembles protection against vacc

257 eractions with NTHi may alter progression of pneumococcal serotypes to diseases of the upper respirat

258 ussis toxin, diphtheria, tetanus and 6 of 10 pneumococcal serotypes varied between 83.0% and 100%, Ha

259 The most common pneumococcal serotypes were 3 (4 episodes), 35B, 9N, 38,

260 Pneumococcal serotypes were identified from urine sample

261 ity specific to one of the approximately 100 pneumococcal serotypes, and typically eliminates it from

262 We evaluated waning immunity to 14 pneumococcal serotypes, pertussis toxin (PT), tetanus to

263 lower antibody levels than controls against pneumococcal serotypes, tetanus, pertussis, and varicell

264 le production and gene expression in several pneumococcal serotypes.

265 reason, we evaluated the concordance between pneumococcal serotyping results by latex agglutination,

266 owed that oral Streptococcus strain SK95 and pneumococcal strain D39 both produce structurally identi

267 rimary human neutrophils were exposed to the pneumococcal strain TIGR4 and its pneumolysin-deficient

268 at an oral streptococcal strain, SK95, and a pneumococcal strain, D39, both produce chemically identi

269 adhesion, conservation of the protein among pneumococcal strains and the lack of human homologue, al

270 Finally, clinical pneumococcal strains of different serotypes were also ab

271 city of the LAMP assay using 41 serotypes of pneumococcal strains.

272 nized protective protein antigens, including pneumococcal surface protein A (PspA) and pneumolysin (P

273 structured, dynamic, deterministic models of pneumococcal transmission in England and Wales to descri

274 njugate vaccines (PCVs) in regions with high pneumococcal transmission is threatened by the persisten

275 Mortality from pneumococcal, tuberculous, and culture-negative meningit

276 tious Diseases Society of America recommends pneumococcal urinary antigen testing (UAT) when identify

277 ost severely impaired the immune response to pneumococcal vaccination (response, 52% [15/29]).

278 ophilus influenzae type b (DTaP-IPV-Hib) and pneumococcal vaccination among previously vaccinated chi

279 lidated in a nationwide (n = 482) and a post-pneumococcal vaccination cohort (n = 121).

280 This is important, as pneumococcal vaccination coverage in PLWH is low in Euro

281 ve the immune response to a T-cell-dependent pneumococcal vaccination in patients with AAV, thus offe

282 ghting the advantages of a diversity of anti-pneumococcal vaccination strategies.

283 unogenicity of PCV20 in adults without prior pneumococcal vaccination.

284 The 13-valent pneumococcal vaccine (PCV13) was introduced for US child

285 n CSF leakage had been vaccinated (23-valent pneumococcal vaccine in 9 patients, meningococcal serogr

286 continue to have an important role in adult pneumococcal vaccine policy, including the possibility o

287 art failure, lung disease, and influenza and pneumococcal vaccine uptake, except aTIV homes housed fe

288 is essential for evaluating and formulating pneumococcal vaccines and for informing vaccine policy.

289 Capsule-targeted pneumococcal vaccines have likely contributed to increas

290 erstand progression to disease and impact of pneumococcal vaccines in the elderly.

291 disease burden after introduction of several pneumococcal vaccines, a UAD-2 assay was developed to de

292 With all serotyped IPD isolates covered by pneumococcal vaccines, our study provides additional arg

293 hich helped countries access more affordable pneumococcal vaccines.

294 erage as compared to the currently available pneumococcal vaccines.

295 s for the development of more broadly-acting pneumococcal vaccines.

296 monitor the clinical value of information on pneumococcal variants in dynamic microbial and susceptib

297 the pathogenic effects related to particular pneumococcal variants, and indicates that information on

298 ase D (AhpD) has been shown to contribute to pneumococcal virulence and oxidative stress responses in

299 e expression of the capsule operon, the main pneumococcal virulence factor, to be externally inducibl

300 ression patterns, such as the ones found for pneumococcal virulence factors.